|Day Low/High||0.03 / 0.03|
|52 Wk Low/High||0.01 / 0.09|
Dr. Scribner to Focus on Accelerated Regulatory Pathway for ESS
- Presentation and Live Webcast on October 9, 2015 at 11:25 a.m. PDT -
Company Simultaneously Repurchases All Outstanding Series G Convertible Preferred Stock
Advisors Bring Over 30 Years of Expertise in Successfully Commercializing Molecular Diagnostics Companies
Top-Line Phase 2b Results Expected in 1H 2016
Amarantus Now Has Full Ownership of Cutanogen Corporation, Which Has Exclusive Worldwide License to Orphan Drug Product Candidate Engineered Skin Substitute (ESS)
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.